Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature ...

ADC Therapeutics (NYSE:ADCT) is one of the best growth stocks to buy right now. On March 10, ADC Therapeutics reported its financial and operational results for Q4 and the full-year 2025, highlighting ...

Caribou Biosciences offers the strongest allogeneic CAR-T data to date, with efficacy and safety. Read why I am bullish about ...

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A., and its Mexican affiliate, ...

An innovative platform developed by PKU researchers called "cf-EpiTracing" has proved capable of detecting and tracing ...

Epigenetic therapies are offering a more targeted way to treat some lymphomas by changing how genes are turned on or off ...

In an interview with Targeted Oncology, Hua-Jay “Jeff” Cherng, MD, assistant professor of medicine in the lymphoma program in ...

Debi Weiss went to the doctor's office with what she thought were worsening flu symptoms, but got a very different diagnosis ...

Giahan Tang thought she was finally finding stability after college when unusual symptoms led to a shock diagnosis of stage 4 diffuse large B-cell lymphoma After an ER visit initially blamed on an ...

Real-time ctDNA MRD testing guides early chemo de-escalation in diffuse large B-cell lymphoma, aiming to cut toxicity without losing cure rates. In an interview with Targeted Oncology, Hua-Jay “Jeff” ...

HealthDay News — Features that characterize presentation of vitreoretinal lymphoma are described in an article published online March 1 in Clinical & Experimental Ophthalmology.